RecruitingObesityOverweightDiabetes Mellitus, Type 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Eligible age

18–75 yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Have type 2 diabetes
✓ Have an HbA1c ≥7.5% to ≤10.5% at screening
✓ Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
✓ Diet and exercise
✓ Stable dose of metformin
✓ Sodium-glucose cotransporter-2 (SGLT2) inhibitor
✓ Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening
✓ Have a BMI of 27 or greater at screening

You may not qualify if…

✕ Have any form of diabetes other than type 2 diabetes
✕ Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
✕ Have any of the following cardiovascular conditions within 3 months prior to screening:
✕ acute myocardial infarction
✕ cerebrovascular accident (stroke)
✕ unstable angina, or
✕ hospitalization due to congestive heart failure
✕ Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include